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Synopsis
Nac1 (nucleus accumbens 1) is a POZ (poxvirus and zinc finger)-domain transcriptional repressor that is expressed
at high levels in ovarian serous carcinoma. Here we identify Nac1 as a novel interacting partner of the POZ-domain
transcriptional activator, Miz1 (Myc-interacting zinc-finger protein 1), and using chemical crosslinking we show that this
association is mediated by a heterodimeric interaction of the Nac1 and Miz1 POZ domains. Nac1 is found in discrete
bodies within the nucleus of mammalian cells, and we demonstrate the relocalization of Miz1 to these structures in
transfected HeLa cells. We show that siRNA (small interfering RNA)-mediated knockdown of Nac1 in ovarian cancer
cells results in increased levels of the Miz1 target gene product, p21Cip1. The interaction of Nac1 with Miz1 may thus
be relevant to its mechanism of tumourigenesis in ovarian cancer.
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INTRODUCTION
Nac1 (nucleus accumbens 1) was originally identified as the pro-
tein product of a cocaine-inducible transcript in the nucleus ac-
cumbens of the rat brain [1], and more recently it has emerged as
a transcriptional repressor that functions as part of the network
involved in embryonic stem cell self-renewal [2]. Amplification
of the gene encoding Nac1, NACC1, has been implicated as one of
the top potential ‘drivers’ in human ovarian serous carcinoma [3],
and high levels of Nac1 may also be relevant in ovarian clear cell
carcinoma [4] and in some cervical [5] and uterine [6] cancers.
Elevated Nac1 levels in ovarian serous carcinoma are particularly
common in drug-resistant disease that is associated with relapse
following initial treatment [7,8]. The artificial knockdown or in-
activation of Nac1 leads to the apoptosis of Nac1-overexpressing
ovarian cancer cells [7] and restores their sensitivity to chemo-
therapeutics [9], thereby validating this protein as a potential
therapeutic target.
A variety of mechanisms are involved in Nac1-mediated tu-
mourigenesis and drug-resistance. Nac1 induces cell proliferation
in part by repressing transcription of the Gadd45GIP1 (growth
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arrest and DNA-damage-inducible 45-γ interacting protein) gene
[10] and negative regulation of the Gadd45 pathway also contrib-
utes to paclitaxel-resistance [11]. Elevated Nac1 also
contributes to tumour aggressiveness and drug-resistance by in-
creasing the levels of FASN (fatty acid synthase) and thereby
modulating fatty acid metabolism. Treatment failure in ovarian
cancer is associated with drug-induced activation of HMGB1-
mediated autophagy and with the inhibition of senescence, and
Nac1 plays an essential role in both of these processes [12,13].
It has recently been shown that Nac1 also has non-nuclear func-
tions, and interacts with monomeric actin to promote cytokinesis
in highly proliferating Nac1-overexpressing cancer cells [14].
Nac1 is a POZ-TF [POZ (poxvirus and zinc finger); also known
as BTB (bric-a`-brac, tramtrack and broad complex)-domain tran-
scription factor] that functions as a repressor in both neuronal and
non-neuronal cells [15,16]. Transcription factor POZ domains
serve to recruit co-repressors and also mediate dimerization and
heteromeric interactions between different POZ-TFs (reviewed
in [17]); the Nac1 POZ domain is a classic POZ-domain di-
mer [18], and interacts with the corepressor COREST [19] and
with the histone deacetylases HDAC3 and HDAC4 [16]. POZ
domains are also found in adaptor proteins that recruit substrates
c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
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for ubiquitination by the cullin-type E3 ligase complexes; these
adaptors interact with cullin3 via their POZ-domain, and they re-
cruit substrates via additional domains such as kelch, MATH or
zinc fingers. It has recently been recognized that some transcrip-
tion factor POZ domains can also interact with cullin3 [20,21]
and thereby play a role in regulating the ubiquitination of their
corepressors and other interacting partners [22,23]. Nac1 inter-
acts with cullin3 in neuronal cells [24], although its role in ubi-
quitination has not been characterized. Target genes of Nac1 have
been identified in embryonic stem cells [25], but the mechanism
whereby Nac1 interacts with DNA is not known. Nac1 does not
contain a zinc-finger DNA-binding domain as is found in most
POZ-TFs; however, it is assumed that its C-terminal BEN (B-cell
translocation gene 3 associated nuclear protein, E5R and Nac1)
domain interacts with the promoters of target genes as has been re-
cently reported for other BEN-domain transcriptional repressors
[26]. Many POZ-domain transcription factors and adaptors are
localized within discrete structures in the nucleus [27], and Nac1
is found in nuclear bodies, termed Nac1 bodies, at specific stages
of the cell cycle [28].
Miz1 (Myc-interacting zinc-finger protein 1) is a POZ-TF
that was originally identified as a c-Myc interacting protein [29]
in yeast two-hybrid protein interaction screens. Miz1 regulates
genes involved in growth arrest [30,31], differentiation [32–34],
apoptosis [35] cell adhesion [36] and autophagy [37], and plays a
central role in DNA-damage responses [38–41], lymphoid devel-
opment [42–45] and inflammation [46]. Miz1 acts as a transcrip-
tional activator via the recruitment of the cofactors p300 [31] and
nucleophosmin [47], and it binds to the initiator DNA element of
target gene promoters via its central zinc-finger DNA-binding do-
main. The transcriptional properties of Miz1 are altered by its in-
teraction with other transcription factors, and it acts as a repressor
when in complex with c-Myc [29], BCL6 [48] or Zbtb4 [49].
Miz1 target genes include the cell cycle inhibitors CDKN1A [39]
and CDKN2B [30,31], the differentiation-associated Mad4 gene
[33], the anti-apoptotic Bcl2 gene [50], the autophagy gene Am-
bra1 [37], and the alpha6 and beta1 integrin genes involved in cell
adhesion [36]. The repression of Miz1 target genes by Miz1/c-
Myc and by Miz1/BCL6 complexes is important in physiolo-
gical apoptotic responses [35] and in B-cell development [48]
respectively; however, the inappropriate repression of cell-cycle
inhibitors contributes to deregulated proliferation in tumours as-
sociated with the overexpression of c-Myc [51,52] or BCL6 [48].
Miz1 interacts with c-Myc via residues adjacent to its DNA-
binding domain [29], and with Zbtb4 and BCL6 via its N-terminal
POZ domain [48,49]. Although most transcription factor POZ do-
mains are dimeric [17], the Miz1 POZ domain forms both dimers
[53] and tetramers in vitro [54]; importantly, the stoichiometry
of heteromeric Miz1 POZ domain interactions has not been
elucidated.
In this report, we identify Nac1 as a novel interacting partner
of Miz1, and show that this interaction is mediated by a heterodi-
meric association between the POZ domains of these proteins.
The interaction of Nac1 with Miz1 leads to the recruitment of
Miz1 into Nac1 nuclear bodies, and the artificial knock-down of
Nac1 in an ovarian cancer cell line results in increased levels of
the Miz-1 target gene product, p21Cip1. The interaction between
Nac1 and Miz1 may thus contribute to tumourigenesis in Nac1-
overexpressing ovarian cancer cells, analogous to the role of the
BCL6/Miz1 interaction in diffuse large cell B-cell lymphoma.
EXPERIMENTAL
Antibodies
Rabbit anti-FLAG polyclonal (Sigma F7425), rabbit anti-HA
(haemagglutinin) polyclonal (Santa Cruz Y-11 [sc-805]), rabbit
anti-p21 polyclonal (Abcam ab7960), mouse anti-Nac1 mono-
clonal (Abcam ab81987) and mouse anti-GAPDH monoclonal
(Calbiochem CB1001) antibodies were used in western blots at
0.5, 2, 5, 0.82 and 1 μg/ml, respectively. Horseradish peroxidase-
conjugated goat anti-rabbit IgG and goat anti-mouse IgG second-
ary antibodies (Pierce 31460 and 31430, respectively) were used
at 40 ng/ml.
Cloning
Mouse Miz1 and Nac1 cDNAs were amplified from an embryonic
stem cell cDNA library using Phusion high-fidelity DNA poly-
merase (Thermo Fisher) and inserted into a vector that expresses
fusion proteins containing an N-terminal 3× FLAG or 3× HA tag
under control of the CMV (cytomegalovirus) promoter. cDNAs
encoding POZ domains were also expressed as fusion proteins
that additionally contain a C-terminal nuclear localization sig-
nal (mouse c-Myc residues 353–361). Miz1 and Nac1 cDNAs
were cloned into pEGFP-C1 or pmCherry-C1 (Clontech Labor-
atories Inc.) for the expression of fluorescently tagged proteins.
Site-directed mutagenesis was carried out by PCR using Phusion
high-fidelity DNA polymerase.
Yeast two-hybrid assays
Yeast two-hybrid assays were performed using Saccharomyces
cerevisiae AH109 transformed with 200 ng of each plasmid DNA
as described in [55]. The mouse Miz1 POZ domain (residues 1–
115) was expressed as a GAL4 activation domain fusion using
the vector pGADT7 (Clontech Laboratories Inc.), and the POZ
domains of 32 mouse transcription factors were expressed as
GAL4 DNA-binding domain fusions using pGBKT7 (Clontech
Laboratories Inc.).
Transfection of mammalian cell lines
HeLa and COS-7 cells were cultured in Eagle’s minimal essen-
tial medium (alpha modification) supplemented with 10 % (v/v)
FBS, 50 units/ml penicillin and 50 μg/ml streptomycin at 37 ◦C
and 5 % (v/v) CO2. COS-7 cells for co-immunoprecipitation ex-
periments were seeded into 90-mm-diameter dishes and trans-
fected with a total of 40 μg DNA using the calcium phosphate
method [56]; cells were harvested 36 h post-transfection. HeLa
cells for fluorescence microscopy experiments were seeded onto
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glass slides in 35-mm-diameter dishes and transfected with a total
of 1 μg DNA using GeneJuice® Transfection Reagent (Novagen).
Co-immunoprecipitation using anti-FLAG resin
Approximately 107 cells were rinsed with PBS, pelleted at
1500 g, and resuspended in 200 μl lysis buffer [50 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 % (v/v) Triton X-100].
Samples were incubated on ice for 30 min and the lysate clarified
by centrifugation at 12 000 g for 10 min at 4 ◦C. Clarified lysate
was added to 20 μl TBS-equilibrated [50 mM Tris–HCl (pH 7.4),
150 mM NaCl] anti-FLAG M2 affinity gel (Sigma) and incub-
ated for 5 h at 4 ◦C. The resin was pelleted by centrifugation at
7000 g for 1 min at 4 ◦C, and washed three times with 1 ml TBS.
The samples were boiled with SDS-sample buffer [125 mM Tris–
HCl (pH 6.8), 4 % (w/v) SDS, 20 % (v/v) glycerol, 0.1 % (w/v)
bromophenol blue] and analysed by western blotting.
Thiol crosslinking in vivo
48 h post-transfection, HeLa cells were rinsed twice in PBS and
incubated for 5 min at 37 ◦C in Kreb’s-Ringer phosphate buffer
[118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4,
1.2 mM MgSO4, 16.2 mM Na2HPO4 (pH 7.4)]. Cells were in-
cubated at 4 ◦C for 5 min and BMB (1,4-bismaleimidobutane)
was added to a final concentration of 100 μM. Crosslinking was
performed at 4 ◦C for 10 min and the reaction was quenched by
the addition of L-cysteine to 4 mM [57]. Cells were rinsed with
PBS, pelleted at 1500 g, resuspended in SDS-sample buffer con-
taining 10 % (v/v) 2-mercaptoethanol, and analysed by western
blotting.
Transfection of A2780 cells with siRNA (small
interfering RNA)
A2780 ovarian cancer cells were cultured in RPMI 1640
medium supplemented with 10 % FBS at 37 ◦C and 5 %
(v/v) CO2 and seeded into 6-well plates at a density
of 1 × 105 cells per well. Cells were incubated for 24 h
and the medium replaced with OPTI-MEM-reduced serum
medium (Invitrogen). 175 pmol ON-TARGETplus SMART-
pool siRNA (Dharmacon; target sequences: CGGCUGAA-
CUUAUCAACCA, GGGCGCAGCUGAUGAACUG, GGG-
CAUGGAUGAGCAGUAC, CGAAAUCGCAUCCGGGUUC)
was delivered into the cells using 35 μl Oligofectamine (In-
vitrogen) as described in the manufacturers protocol. Control
cells were treated with 175 pmol non-targeting ON-TARGETplus
siRNA (Dharmacon). Cells were incubated for 4 h at 37 ◦C/5 %
CO2 before being supplemented with FBS to a final concentra-
tion of 10 %. Cells were harvested 48 h post-transfection, boiled
in SDS-sample buffer containing 10 % (v/v) 2-mercaptoethanol
and analysed by western blotting.
Fluorescence microscopy
Fluorescence microscopy was carried out using the DeltaVision
Optical Restoration Microscopy System (Applied Precision Inc.).
Images were collected from 50 × 0.2 μm thick optical sections,
Figure 1 Interaction of the Nac1 and Miz1 POZ domains in yeast
two-hybrid assays
AH109 yeast cells were transformed with constructs expressing GAL4
activation domain fusion proteins (pGADT7) together with GAL4 DNA–
binding domain fusion proteins (pGBKT7) and plated onto media lacking
leucine and tryptophan [-LT], lacking leucine, tryptophan and histidine
[-HLT], and lacking leucine, tryptophan, histidine and adenine [-LTHA].
Transformation with Miz1POZ-pGADT7 together with: (1) pGBKT7, (2)
Zbtb8 POZ-pGBKT7, (3) Zbtb6 POZ-pGBKT7, (6) Nac1 POZ-pGBKT7, and
(7) BCL6 POZ-pGBKT7 (7). Transformation with Nac1 POZ-pGBKT7 to-
gether with: (4) Zbtb8 POZ-pGADT7, (5) Zbtb6-pGADT7 and (8) pGADT7.
and 3D datasets were deconvoluted using the default settings on
the softWoRx deconvolution algorithm (Applied Precision Inc.).
RESULTS AND DISCUSSION
Miz1 interacts with Nac1 in yeast two-hybrid
assays and in mammalian cells
The transcriptional properties of Miz1 may be modulated by
the interaction of its N-terminal POZ domain with other POZ
domain transcription factors [48]. To identify novel interacting
partners of Miz1, we used yeast two-hybrid assays to analyse the
interaction of its POZ domain (Miz1 residues 1–115) with the
POZ domains isolated from 32 POZ-TFs; the well-characterized
interaction between the Miz1- and BCL6 POZ domains served
as a positive control. The Miz1 POZ domain interacted strongly
with the POZ domain of the transcriptional repressor, Nac1, in
these assays (Figure 1, panel 6).
To determine whether Nac1 interacts with Miz1 in
mammalian cells, we expressed the full-length proteins,
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Figure 2 Co-immunoprecipitation of Nac1 and Miz1 in transfected HeLa cells
(a) HeLa cells were transfected with FLAG-tagged Nac1 and HA-tagged Miz1 constructs. Lysates were immunoprecipitated
using anti-FLAG resin, and samples analysed by western blotting using anti-HA antibody. (b) HeLa cells were transfected
with FLAG-tagged Nac1 POZ domain constructs together with constructs that expressed the Miz1, Zbtb8 and Zbtb6 POZ
domains.
FLAG-Nac12 − 514 (FLAG-tagged Nac1) and HA-Miz12 − 794
(HA-tagged Miz1), in COS-7 cells and analysed their inter-
action by co-immunoprecipitation using anti-FLAG resin; we
also analysed the interaction between FLAG-Nac12 − 514 and a
truncated protein comprising the Miz1 POZ domain only (HA-
Miz1 POZ2 − 115). FLAG-Nac12 − 514 interacted both with HA-
Miz12 − 794 and with HA-Miz1 POZ2 − 115 in these assays (Fig-
ure 2a, lanes 1 and 2), and deletion of the Nac1 POZ domain
(FLAG-Nac1127 − 514) abolished these associations (Figure 2a,
lanes 3 and 4). We also expressed the N-terminal POZ do-
main of Nac1 as a FLAG-tagged protein (FLAG-Nac12 − 175),
and demonstrated its interaction both with HA-Miz12 − 794 and
with HA-Miz1 POZ2 − 115 (Figure 2a, lanes 7 and 8).
To confirm the specificity of the interaction between the Nac1
and Miz1 POZ domains in mammalian cells, we analysed the
interaction of the Nac1 POZ domain with the POZ domains of
the zinc-finger proteins Zbtb6 and Zbtb8; these POZ domains did
not interact with Nac1 in yeast two-hybrid assays (Figure 1). The
Nac1 POZ domain was expressed as two FLAG-tagged proteins,
FLAG-Nac12 − 125 and FLAG-Nac12 − 175, both of which interac-
ted with the Miz1 POZ domain, but not with Zbtb6 or Zbtb8
(Figure 2b).
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Figure 3 The interaction between Nac1 and Miz1 leads to the relocalization of Miz1 into Nac1 nuclear bodies
HeLa cells were transfected with constructs that expressed EGFP (enhanced GFP)-tagged and pmCherry-tagged proteins
as indicated.
The interaction between Nac1 and Miz1 leads to
the relocalization of Miz1 into Nac1 nuclear bodies
The nucleus contains distinct nuclear bodies that compartment-
alize the organelle to facilitate efficient biological processes (re-
viewed in [58]). Several POZ-domain transcription factors and
Cul3 adaptors are found in discrete nuclear structures that have
variously been termed bodies or speckles [27], and the local-
ization of these POZ proteins in nuclear bodies directs the co-
localization of their interacting partners [23,59]. Nac1 is found
in discrete bodies within the nucleus of normal and cancer cells
[7]; although it has not been determined whether these structures
play a role in transcriptional regulation or protein ubiquitination,
it is conceivable that they could represent hubs that recruit and
silence multiple specific gene loci in a manner similar to the
repressive function of polycomb bodies (reviewed in [58]). In
order to determine whether the subcellular localization of Miz1
is modulated by its interaction with Nac1, we expressed fluor-
escently tagged Miz1 and Nac1 proteins in HeLa cells. When
expressed individually, mCherry-Nac12 − 794 (mCherry-tagged
full-length Nac1) was found in nuclear bodies, consistent with
previous reports, whereas GFP-Miz12 − 794 (green fluorescent
protein-tagged full-length Miz1) showed diffuse nuclear floures-
cence (Figure 3a). The co-expression of GFP-Miz12 − 794 with
mCherry-Nac12 − 794 led to its relocalization into Nac1 nuclear
bodies (Figure 3b).
siRNA-mediated knock-down of Nac1 leads to the
induction of the Miz1 target gene product, p21Cip1,
in ovarian cancer cells
The interaction of Miz1 with the transcription factors c-Myc or
BCL6 leads to the suppression of Miz1 target genes associated
with growth arrest and differentiation [30,31,39,48], and this may
contribute to aberrant growth control in malignancies associated
with the overexpression of these oncoproteins. Nac1is overex-
pressed in advanced ovarian serous carcinoma and is found at high
levels in the human ovarian cancer cell line, A2780. We therefore
determined the effect of siRNA-mediated knock-down of Nac1
on levels of the p21Cip1 protein product of the Miz1 target gene,
CDKN1A, in A2780 cells. Treatment of A2780 ovarian cancer
cells with an siRNA that targets Nac1 led to a 2.6-fold reduction
in Nac1 levels, and a concomitant 7.7-fold increase in levels of
p21Cip1 (Figure 4), consistent with repression of CDKN1A gene
by the Nac1/Miz1 complex in these cells.
The Nac1 and Miz1 POZ domains form a
heterodimeric complex
Transcription factor POZ domains are obligate domain-swapped
dimers that have an extensive hydrophobic interface that mainly
comprises residues from the N-terminal α helices of each chain
[60,61] (reviewed in [17]); a tetrameric association of the Miz1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
231
Au
tho
r C
op
y
M. A. Stead and S. C. Wright
Figure 4 siRNA-mediated knockdown of Nac1 leads to the induc-
tion of p21Cip1 in A2780 ovarian carcinoma cells
A2780 cells were treated with siRNA that targets Nac1 or with control
siRNA, and levels of Nac1, p21Cip1 and GAPDH were measured by
western blotting.
POZ domain has also been observed [54]. Crucially, the stoi-
chiometry of heteromeric POZ domain interactions has not been
experimentally determined, and we therefore attempted to de-
termine whether the Miz1- and Nac1 POZ domains are capable
of forming a heterodimeric species.
The POZ domain transcription factor, Bach2, contains a
cysteine residue (Cys20) located in the N-terminal alpha helix
(α1) of the POZ domain, and crystal structures of the Bach2
POZ domain dimer revealed an inter-subunit disulphide bond
between the Cys20 residues of the two chains (PDB entries 3ohu
and 3ohv [62]). We used crystal structures of the Nac1 and
Miz1 POZ domains (PDB entries 3ga1 and 2q81) to model
a cysteine residue in place of the residue (Nac1 Gly13 and
Miz1 Ser7) corresponding to Bach2 Cys20; the proximity of
the cysteine residues in the mutant POZ domain models sug-
gested that Nac1[G13C] and Miz1[S7C] would each be capable of
forming disulphide-bonded homodimers. We also mutated the
Cys19 residue of the Nac1 POZ domain α1 helix in order to
prevent potential spurious disulphide bond formation between
nearby cysteine residues; this cysteine residue is not conserved
among the POZ domains of other proteins. Mutant Nac1 and
Miz1 POZ domains, Nac1[G13C C19S] and Miz1[S7C], were ex-
pressed as FLAG-tagged proteins in COS-7 cells; the Miz1 POZ
domain was expressed as two forms of FLAG-tagged protein
(FLAG-Miz1 POZ2 − 115 and FLAG-Miz1 POZ2 − 165) that were
readily distinguishable in size, and the Nac1 POZ domain was
expressed as FLAG-Nac1 POZ2 − 125. As expected, neither of the
wild-type Miz1 POZ domains, FLAG-Miz1 POZ2 − 115 or FLAG-
Miz1 POZ2 − 165, formed disulphide-bonded species when ex-
pressed in COS-7 cells and treated with the thiol crosslinking
reagent BMB (Figure 5a, lanes 1–3). In contrast, the BMB-
treated mutant Miz1 POZ domains, FLAG-Miz1 POZ2 − 115 [S7C]
and FLAG-Miz1 POZ2 − 165 [S7C], each formed disulphide-bonded
dimers when expressed individually (Figure 5a, lanes 4 and
5), and when expressed together produced an additional spe-
cies consistent with heterodimerization between the two proteins
(Figure 5a, lane 6). Similarly, the wild-type Nac1 POZ domain,
FLAG-Nac1 POZ2 − 125, was unable to form a disulphide-bonded
dimer when expressed in COS-7 cells either alone or with the
wild-type FLAG-Miz1 POZ2 − 165 (Figure 5b, lanes 1 and 3). The
mutant FLAG-Nac1 POZ2 − 125 [G13C C19S] formed a disulphide-
bonded dimer (Figure 5b, lane 4) when expressed alone in COS-
7 cells, and when FLAG-Nac1 POZ2 − 125 [G13C C19S] and FLAG-
Miz1 POZ2 − 165 [S7C] were expressed together and treated with
BMB, an additional species was produced that was consistent
with heterodimerization between the Nac1 and Miz1 POZ do-
mains (Figure 5b, lane 6).
Figure 5 The Nac1 and Miz1 POZ domains form a heterodimeric species when expressed in COS-7 cells
(a) COS-7 cells were transfected with FLAG-tagged wild-type and mutant Miz1 POZ domains and treated with BMB. Lysates
were analysed by western blotting using anti-FLAG antibody. (b) COS-7 cells were transfected with FLAG-tagged Nac1 and
Miz1 POZ domains and treated as in (a).
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CONCLUSION
Identification of the Miz1/Nac1 interaction expands the reper-
toire of interactions involving the Miz1 POZ domain and may
have relevance to the mechanism of tumourigenesis by Nac1 in
ovarian cancer. The recent identification of Nac1 as a direct tar-
get gene that is activated by Miz1 [37] may also suggest that the
Miz1/Nac1 interaction could contribute to the autoregulation of
Nac1 expression and of autophagy. The interaction between the
Nac1 and Miz1 POZ domains represents a heterodimeric associ-
ation and it will be relevant to determine both the stoichiometry
of other heteromeric POZ domain interactions and the features
that determine their specificity.
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